Clinical characteristics of pulmonary large cell neuroendocrine carcinoma and a nomogram model for predicting its prognosis

Qiao YANG; Zihan XU; Linpeng ZHENG; Mingjing CHEN; Yongxin YU; Jianguo SUN

doi:10.16016/j.1000-5404.201812070

您当前的位置：

首页 >

文章列表页 >

Clinical characteristics of pulmonary large cell neuroendocrine carcinoma and a nomogram model for predicting its prognosis

Basic Medicine | 更新时间：2026-01-09

- Clinical characteristics of pulmonary large cell neuroendocrine carcinoma and a nomogram model for predicting its prognosis
- Journal of Third Military Medical University Vol. 41, Issue 12, Pages: 1156-1160(2019)
- 作者机构：
  
  400037 重庆，陆军军医大学(第三军医大学)第二附属医院全军肿瘤研究所
- 作者简介：
- 基金信息：
  
  Supported by the General Program of National Natural Science Foundation of China(81773245);the General Program of National Natural Science Foundation of China(81672841);the Cultivation Program for Clinical Research Talents of Army Medical University in 2018(2018XLC1010)
- DOI：10.16016/j.1000-5404.201812070
  CLC： R181.23;R730.7;R734.2
- Received：07 December 2018，
  
  Revised：2019-02-02，
  
  Published：30 June 2019
- 稿件说明：
移动端阅览
Qiao YANG, Zihan XU, Linpeng ZHENG, et al. Clinical characteristics of pulmonary large cell neuroendocrine carcinoma and a nomogram model for predicting its prognosis[J]. Journal of Third Military Medical University, 2019, 41(12): 1156-1160.
DOI：

Qiao YANG, Zihan XU, Linpeng ZHENG, et al. Clinical characteristics of pulmonary large cell neuroendocrine carcinoma and a nomogram model for predicting its prognosis[J]. Journal of Third Military Medical University, 2019, 41(12): 1156-1160. DOI： 10.16016/j.1000-5404.201812070.

摘要

目的

基于监测、流行病学和结果数据库(Surveillance

Epidemiology

and End Results，SEER)，分析肺大细胞神经内分泌癌(pulmonary large cell neuroendocrine carcinoma

PLCNEC)的临床特征和患者生存情况，建立预后模型。

方法

从SEER数据库中收集2004-2013年诊断为PLCNEC的患者1 656例，描述其基本临床特征，通过Kaplan-Meier法绘制生存曲线并进行生存分析。使用Cox比例风险模型探索与总生存期(overall survival，OS)相关的临床特征，并建立可视化的预测患者预后的列线图(nomogram)模型，通过重复抽样对模型进行验证。

结果

1 656例PLCNEC患者中，男性(55.37%)和诊断年龄≥65岁(52.05%)居多，以白种人(84.12%)为主；40.94%做过手术治疗，37.80%做过放疗，51.93%做过化疗。生存分析发现：患者中位生存期为11个月，1年生存率为46.5%。Cox比例风险模型多因素分析发现：女性、黑种人及其他种族、手术治疗、放疗及化疗为保护因素，而年龄≥65岁，肿瘤长径增大，肿瘤向邻近组织、区域淋巴结及远处扩散为危害因素，肿瘤部位对生存影响无明显差异。利用上述与OS相关的临床特征，建立可视化列线图模型，可通过基本临床特征来预测PLCNEC患者的1年生存率。重复抽样验证发现该模型1年生存率预测值与实际值一致性较好(C-index为0.76)。

结论

PLCNEC患者中位OS为11个月，1年生存率为46.5%；性别、诊断年龄、种族、基线肿瘤长径、肿瘤扩散、手术治疗、放射治疗及化疗等临床特征与PLCNEC生存预后相关；成功建立可视化列线图模型，可预测PLCNEC患者1年生存率。

Abstract

Objective

To analyze the clinical characteristics and survival of patients with pulmonary large cell neuroendocrine carcinoma (PLCNEC) and construct a nomogram model for predicting its prognosis.

Methods

We searched the Surveillance

Epidemiology

and End Results (SEER) database to collect the data of patients diagnosed with PLCNEC between 2004 and 2013. Kaplan-Meier method was used for survival analysis of the patients. A Cox proportional hazard model was used to identify the factors affecting the overall survival (OS)

and the significant factors were used to construct a nomogram model for predicting the patients' 1-year survival probability. The discrimination power of this model was assessed based on the C-index

and the calibration was evaluated with a bootstrap procedure.

Results

A total of 1 656 cases of PLCNEC with complete record of the clinical characteristics were collected. Of these patients

55.37% were male

52.05% were above 65 years of age at diagnosis

and 84.12% were white; 51.93% of the patients received chemotherapy

40.94% had surgeries

and 37.80% had radiotherapy. Kaplan-Meier survival analysis showed that the median OS of patients with PLCNEC was 11 months

and their 1-year survival rate was 46.5%. Multivariate analysis identified a female gender

black race

surgery

radiotherapy and chemotherapy as the protective factors

while an age ≥65 years

an increased tumor size

invasion of adjacent tissues

lymph node involvement and distant metastasis were the risk factors for poor prognosis; the primary tumor sites did not significantly affect the survival outcomes of the patients. We established a nomogram model for predicting the 1-year survival probability of the patients based on the significant factors identified in the multivariate analysis. The C-index of this prediction model was 0.76

and assessment of calibration showed that the 1-year survival rate predicted by this model was highly consistent with the observed 1-year survival rate of the patients.

Conclusion

According to the data from SEER

patients with PLCNEC have a median OS of 11 months and a 1-year survival rate of 46.5%. Gender

age

race

tumor size

tumor growth and metastasis and interventions are all associated with the OS of the patients. The nomogram model we established based on the clinical characteristics of PLCNEC is capable of predicting the 1-year survival probability of the patients.

关键词

Keywords

references

FASANO M, DELLA CORTE C M, PAPACCIO F, et al. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy[J]. J Thorac Oncol, 2015, 10(8): 1133-1141. DOI: 10.1097/JTO.0000000000000589.

VARLOTTO J M, MEDFORD-DAVIS L N, RECHT A, et al. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas?[J]. J Thorac Oncol, 2011, 6(6): 1050-1058. DOI: 10.1097/JTO.0b013e318217b6f8.

TRAVIS W D, BRAMBILLA E, NICHOLSON A G, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification[J]. J Thorac Oncol, 2015, 10(9): 1243-1260. DOI: 10.1097/JTO.0000000000000630.

DERKS J L, HENDRIKS L E, BUIKHUISEN W A, et al. Clinical features of large cell neuroendocrine carcinoma: a population-based overview[J]. Eur Respir J, 2016, 47(2): 615-624. DOI: 10.1183/13993003.00618-2015.

TRAVIS W D. Advances in neuroendocrine lungtumors[J]. Ann Oncol, 2010, 21(Suppl 7): vii65-vii71. DOI: 10.1093/annonc/mdq380.

DERKS J L, LEBLAY N, LANTUEJOUL S, et al. New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management[J]. J Thorac Oncol, 2018, 13(6): 752-766. DOI: 10.1016/j.jtho.2018.02.002.

REKHTMAN N, PIETANZA M C, HELLMANN M D, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets[J]. Clin Cancer Res, 2016, 22(14): 3618-3629. DOI: 10.1158/1078-0432.CCR-15-2946.

KUJTAN L, MUTHUKUMAR V, KENNEDY K F, et al. The role of systemic therapy in the management of stage Ⅰ large cell neuroendocrine carcinoma of the lung[J]. J Thorac Oncol, 2018, 13(5): 707-714. DOI: 10.1016/j.jtho.2018.01.019.

SARKARIA I S, IYODA A, ROH M S, et al. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience[J]. Ann Thorac Surg, 2011, 92(4): 1180-1186; discussion 1186-7. DOI: 10.1016/j.athoracsur.2011.05.027.

NAIDOO J, SANTOS-ZABALA M L, IYRIBOZT, et al. Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes[J]. Clin Lung Cancer, 2016, 17(5): e121-e129. DOI: 10.1016/j.cllc.2016.01.003.

DERKS J L, VAN SUYLEN R J, THUNNISSEN E, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?[J]. Eur Respir J, 2017, 49(6): 1601838. DOI: 10.1183/13993003.01838-2016.

CHEN L P, HAN X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, andfuture[J]. J Clin Invest, 2015, 125(9): 3384-3391. DOI: 10.1172/JCI80011.

HELLMANN M D, CALLAHAN M K, AWAD MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer[J]. Cancer Cell, 2019, 35(2): 329. DOI: 10.1016/j.ccell.2019.01.011.

EICHHORN F, HARMS A, WARTH A, et al. PD-L1 expression in large cell neuroendocrine carcinoma of the lung[J]. Lung Cancer, 2018, 118: 76-82. DOI: 10.1016/j.lungcan.2018.02.003.

ZHAO Y Z, CASTONGUAY M, WILKE D, et al. Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma[J]. Curr Probl Cancer, 2019, 43(1): 54-65. DOI: 10.1016/j.currproblcancer.2018.05.006.

IASONOS A, SCHRAG D, RAJ G V, et al. How to build and interpret a nomogram for cancer prognosis[J]. J Clin Oncol, 2008, 26(8): 1364-1370. DOI: 10.1200/JCO.2007.12.9791.

WIERDA W G, O'BRIEN S, WANG X M, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia[J]. Blood, 2007, 109(11): 4679-4685. DOI: 10.1182/blood-2005-12-051458.

BALACHANDRAN V P, GONEN M, SMITH J J, et al. Nomograms in oncology: more than meets the eye[J]. Lancet Oncol, 2015, 16(4): e173-e180. DOI: 10.1016/S1470-2045(14)71116-7.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction and verification of a nomogram prediction model for vascular plaque stability in patients with progressive cerebral infarction based on serum MCP-1, MCPIP1 combined with inflammatory factors

基于CT影像组学特征联合临床特征预测非小细胞肺癌EGFR突变状态

Construction and evaluation of a nomogram risk prediction model for post-hepatectomy liver failure in hepatocellular carcinoma patients with hepatitis B infection at low viral load

Construction and validation of a prognostic model for NK/T-cell lymphoma based on random survival forest algorithm

Construction and validation of a risk prediction model for high altitude de-acclimatization syndrome

Related Author

LI Yanda

SONG Yan

CHEN Yalun

LI Xu

WANG Minheng

ZHANG Hui

YANG Taotao

WANG Xianqi

Related Institution

Department of Neurology， Nanyang Second People’s Hospital， Xinxiang Medical College

Department of Anesthesiology， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Health Statistics， Faculty of Military Preventive Medicine， Army Medical University （Third Military Medical University）

Center for Hematology， First Affiliated Hospital， Army Medical University （Third Military Medical University）

⁰